Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Providing nurses and MAs with an educational video on standardized hair loss photo techniques increased the quantity and quality of documented pictures.

Targeted Education for Standardized Photo Documentation May Improve Hair Loss Care

In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.

Real-World Study Affirms Baricitinib’s Efficacy for Alopecia Areata

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

Adults with Severe Alopecia Improve Anxiety, Depression with Deuruxolitinib Use

This session was titled ‘The Hidden Undercurrent: When Hair Loss Isn’t Alopecia Areata’ and was presented at the DERM 2025 conference by April Armstrong, MD, MPH.

Strategies for Differentiating Hair Loss Disorders from Alopecia Areata

Topline results from the first of 2 studies in the UP-AA program show upadacitinib 15 mg and 30 mg met the primary endpoint for scalp hair coverage.

Upadacitinib Improves Scalp Hair Coverage in Phase 3 UP-AA Trial for Alopecia Areata

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry. 

The Medical Sisterhood: From MD to Medical Director—A Real Talk on Industry Careers

This interview with Friedman highlights the takeaways from his DERM 2025 session on managing chronic pruritus in dermatology.

Discussing Strategies to Manage Chronic Itch Among Patients, with Adam Friedman, MD

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

Patient-Reported Hair Satisfaction with Deuruxolitinib for Severe Alopecia Areata

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.